Please login to the form below

Not currently logged in
Email:
Password:

TDF

This page shows the latest TDF news and features for those working in and with pharma, biotech and healthcare.

Positive trial results for Janssen’s Symtuza boosts its HIV credentials

Positive trial results for Janssen’s Symtuza boosts its HIV credentials

laboratory parameters compared to F/TDF (emtricitabine/tenofovir disproxil fumarate). ... TDF - in HIV-1 positive treatment-naïve adult patients.

Latest news

  • Gilead's Hepatitis B therapy Vemlidy granted EU approval Gilead's Hepatitis B therapy Vemlidy granted EU approval

    Vemlidy (tenofovir alafenamide, TAF) is a once-daily oral treatment, and produces a similar antiviral efficacy to its predecessor Viread (tenofovir disoproxil fumarate, TDF) but at only 10% of the dosage. ... With less tenofovir in the bloodstream, TAF

  • Gilead gets EU nod for TAF-based triple therapy for HIV Gilead gets EU nod for TAF-based triple therapy for HIV

    It is a follow up to Gilead's $1.4bn Complera, which contains emtricitabine, rilpivirine and tenofovir disoproxil fumarate (TDF) and is among the most prescribed HIV drugs. ... TAF is a new salt form of TDF that is ten-fold more potent and can be

  • Gilead bags EU approval for next-generation HIV drug Gilead bags EU approval for next-generation HIV drug

    Clinical trials have shown that TAF is safer than TDF in terms of renal toxicity and bone demineralisation, to recognised toxicities associated with the original drug. ... Gilead is in the process of replacing all its TDF-based HIV drugs with TAF

  • Gilead boosts liver disease pipeline with $1.2bn acquisition Gilead boosts liver disease pipeline with $1.2bn acquisition

    The FDA's approval was based on phase III trials of the tenofovir alafenamide (TAF) based regimen showing non-inferiority to a tenofovir disoproxil fumarate (TDF) regimen and improvement in bone

  • Gilead wins US approval for second TAF-based HIV drug Gilead wins US approval for second TAF-based HIV drug

    The new drug is a follow-up to Gilead's Complera - which contains emtricitabine, Janssen's rilpivirine and tenofovir disoproxil fumarate (TDF) - but replaces the latter with a new salt of ... Gilead is in the process of replacing its TDF-based HIV

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics